Dietary Reporting in the Amyloidoses
Part of paid clinical trials in Detroit, Michigan.
- Sponsor
- Barbara Ann Karmanos Cancer Institute
- Study ID
- NCT05738005
- Status
- Recruiting
Conditions
- Amyloidosis
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Tracking Dietary/Supplement Intake on MyFitnessPal smartphone application (app) — OTHERAmyloidosis patients will use MyFitnessPal application to track dietary intake and use of herbal/alternative supplements in from week 2-9. Patient's usage of the application and questionnaires completed by the patient at the start, Week 2 and Week 10 will determine feasibility.
Study Details
The goal of this clinical trial is to learn about malnutrition and weight loss in patients with Amyloidosis. The main question it aims to answer is: Is it feasible to use a low-cost nutrition-based application (apps) for use on a smartphone to obtain detailed information on caloric intake in Amyloidosis patients Participants will be asked to: * Download the MyFitnessPal application on their smartphone and view an online tutorial * After a week of practice, from weeks 2-9, participants will enter daily dietary intake as well as daily herbal/alternative supplement intake into the MyFitnessPal application on their smartphone. * complete a questionnaire prior to starting the application, after week 2 and at week 10 after starting the application
Key Dates
- Start date
- Mar 2, 2023
- Status verified
- Jan 2025
- Primary completion
- Nov 21, 2025
- Completion
- Nov 21, 2025
Study Design
- Enrollment
- 40 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- HEALTH_SERVICES_RESEARCH
Arms
- Other: Tracking Dietary/Supplement Intake on MyFitnessPal smartphone application (app)MyFitnessPal smartphone application is used to track daily dietary intake and herbal/alternative supplements.
Primary Outcome Measure
Adherence Rate [ Time Frame: 56 days ]
Central Contacts
- Jeffrey Zonder, MD313-576-8732
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Karmanos Cancer Institute | Detroit | Michigan | 48201 | Andrew Kin, M.D. Navid Mahabadi, D.O. Felicity WK Harper, PhD Jennifer Beebe-Dimmer, PhD Jacob Katzman Abdul Khan, M.D. |
Find similar trials in Detroit, MI
Related Studies
- Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR VariantPHASE3 · Recruiting · Eidos Therapeutics, a BridgeBio company · La Jolla, California
- A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.PHASE1/PHASE2 · Recruiting · Alexion Pharmaceuticals, Inc. · Phoenix, Arizona
- Registry for Adults With Plasma Cell Disorders (PCD's)Recruiting · UNC Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina
- Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)PHASE2 · Recruiting · University of Alabama at Birmingham · Birmingham, Alabama